Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if BMS-663513 administered in combination with
ipilimumab to patients with advanced malignant melanoma is safe and tolerable